Appointments

866.223.8100

Submit a Form

Questions

866.223.8100

Submit a Form

Expand Content

View Cancer Clinical Trials

CASE 4107   |   CC385
Clinical Study to Assess Entry of Chemotherapeutic Agents into Brain Metastases in Women with Breast Cancer

Disease(s)
Brain
Breast
Hospital(s)
Main Campus
Phase(s)
Stage(s)
Type(s)
Therapeutic
Drug(s)

Contact Information
Cancer Answer Line

866.223.8100

8:00 am - 4:30 pm, Monday - Friday


Description
  1. To determine the concentration of certain chemotherapeutic drugs in brain metastases from breast cancer

Inclusion Criteria
  1. Age ≥ 18
  2. Histologically or cytologically documented breast carcinoma with suspected or known parenchymal brain metastases for which surgical resection or biopsy is clinically indicated.
  3. Karnofsky performance status ≥ 50
  4. Life expectancy of ≥3 months
  5. Patients must have the following laboratory parameters:
    • Absolute granulocyte count ≥ 1500/mm3
    • Platelet count ≥ 100,000 /mm3
    • Hemoglobin ≥ 10 gm/dl
    • Creatinine ≤ 1.5 x normal
    • Bilirubin (total) ≤ 1.5 x normal
    • AST ≤ 3 x normal
  6. Off cytotoxic chemotherapy ≥ 3 weeks (6 weeks for nitrosoureas, mitomycin-C).
  7. Patients may continue hormone therapy and trastuzumab.
  8. The patient's treating oncologist must agree that the patient would derive clinical benefit from receiving at least one of the following agents: capecitabine, cyclophosphamide, doxorubicin, gemcitabine, lapatinib, paclitaxel, trastuzumab, or vinorelbine
  9. Off cranial radiation therapy ≥ 4 weeks
  10. Women of childbearing potential must have a negative urine or serum pregnancy test at screening.
  11. All patients of reproductive potential must agree to use an effective method of contraception during the study and three months following termination of treatment.

Exclusion Criteria
  1. Any toxicity > grade 2 felt to be from prior chemotherapy or radiation therapy at time of study entry.
  2. Patients who have received cytotoxic chemotherapy within 3 weeks (2 weeks for non-cytotoxic drugs [e.g., small molecule targeted drugs] and 6 weeks for nitrosoureas, mitomycin-C)
  3. Patients who have received bevacizumab in past 60 days
  4. Patients taking any experimental therapies
  5. Severe cardiac insufficiency (NYHA III or IV), with uncontrolled and/or unstable cardiac or coronary artery disease.
  6. Pregnant or lactating females
  7. A history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits.

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.